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The C terminus is responsible for all of the agonist
activity of C5a at human C5a receptors (C5aRs). In this
report we have mapped the ligand binding site on the
C5aR using a series of agonist and antagonist peptide
mimics of the C terminus of C5a as well as receptors
mutated at putative interaction sites (Ile116, Arg175,
Arg206, Glu199, Asp282, and Val286). Agonist peptide 1
(Phe-Lys-Pro-D-cyclohexylalanine-cyclohexylalanine-D-
Arg) can be converted to an antagonist by substituting
the bulkier Trp for cyclohexylalanine at position 5 (pep-
tide 2). Conversely, mutation of C5aR transmembrane
residue Ile116 to the smaller Ala (I116A) makes the recep-
tor respond to peptide 2 as an agonist (Gerber, B. O.,
Meng, E. C., Dotsch, V., Baranski, T. J., and Bourne, H. R.
(2001) J. Biol. Chem. 276, 3394–3400). However, a potent
cyclic hexapeptide antagonist, Phe-cyclo-[Orn-Pro-D-cy-
clohexylalanine-Trp-Arg] (peptide 3), derived from pep-
tide 2 and which binds to the same receptor site, re-
mains a full antagonist at I116AC5aR. This suggests that
although the residue at position 5 might bind near to
Ile116, the latter is not essential for either activation or
antagonism. Arg206 and Arg175 both appear to interact
with the C-terminal carboxylate of C5a agonist peptides,
suggesting a dynamic binding mechanism that may be a
part of a receptor activation switch. Asp282 has been
previously shown to interact with the side chain of the
C-terminal Arg residue, and Glu199 may also interact
with this side chain in both C5a and peptide mimics.
Using these interactions to orient NMR-derived ligand
structures in the binding site of C5aR, a new model of
the interaction between peptide antagonists and the
C5aR is presented.
C5a, a 74-residue polypeptide, is involved in several stages of
inflammatory processes, causing chemotaxis and degranula-
tion of leukocytes, enhancing vascular permeability, and stim-
ulating cytokine production (2). The C terminus of C5a is rap-
idly truncated in vivo to C5a des-Arg74 (3), a plasma-stable
form that has a different spectrum of bioactivity to that of
intact C5a (4). Peptide analogs of the C-terminal domain of C5a
(e.g. Phe-Lys-Pro-D-Cha-Cha-D-Arg, peptide 1) (5) are report-
edly full agonists at the C5a receptor (C5aR).1 This suggests
that the C terminus is solely responsible for receptor activa-
tion, the remainder of the molecule conferring high affinity
binding (6–8). C5aR is a member of the G protein-coupled
receptor superfamily (9, 10), two of the extracellular loops (the
second and third) and the N-terminal domain being essential
for C5a binding (11). The receptor N terminus is required for
high affinity binding of C5a but not for receptor activation by
C5a or small peptide agonists (12), which interact with charged
residues at the extracellular faces of the transmembrane heli-
cal bundle and hydrophobic residues in the core of the receptor
(13–15). The nature of the residue at position 5 of 1 has been
shown to be crucial for agonist activity (5), with substitution by
bulkier, more aromatic molecules such as Trp or 1-naphthyl-
alanine reducing agonist activity (5). Two derivatives of 1, the
linear peptide antagonist Phe-Lys-Pro-D-cyclohexylalanine-
Trp-D-Arg, 2, (5) and the cyclic peptide antagonist Phe-cyclo-
[L-Orn-Pro-D-cyclohexylalanine-Trp-Arg], 3, have been shown
to inhibit C5a binding and function at human and rat C5aR
(16–18).
A model for the interaction of antagonist 2 with C5aR has
recently been proposed using data from a yeast-based system of
genetic analysis. Antagonist 2 became a full agonist at the
I116A-mutated C5aR. This was interpreted as suggesting that
Ile116 in transmembrane helix 3 could be part of an activation
switch that is blocked by Trp5 in antagonist 2 (1). An adjacent
receptor residue, Val286, in helix 7, was also suggested to con-
tribute to the mechanism. The C-terminal carboxylate has been
shown to be involved in the interaction between 2 and C5aR,
possibly at Arg175 in helix 4 or Arg206 in helix 5 (6, 13). On the
other hand, cyclic compound 3, in which there is no free car-
boxylate, is an even more potent antagonist than 2, so its
antagonist properties are likely dependent upon only its Trp5
residue, the C terminus being blocked. The side chain of the
C-terminal Arg74 residue of C5a has been shown to interact
with Asp282 at the extracellular side of helix 7 (14). Glu199, near
the extracellular face of helix 5, appears to interact with the
side chain of Lys68, a residue required for full activity in ago-
nist peptides and C5a des-Arg74 but not intact C5a (19, 20).
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In this paper we report the effects of mutating Ile116, Val286,
Arg175, Glu199, Arg206, and Asp282 on the activity of C5a, C5a
des-Arg74, and a series of peptide agonists and antagonists. The
data suggest that residues other than Ile116 and Val286 may be
involved in the mechanism of antagonist action for cyclic an-
tagonist 3 and perhaps also for acyclic ligands. However, the
substitution of a more bulky hydrophobic residue for Trp5 in 3
does produce a peptide with very weak agonist activity at
I116A-C5aR, suggesting that Ile116 may lie in close proximity
to this ligand residue as well. Together with evidence for in-
teractions between the C-terminal Arg6 of the peptides and
Arg175, Glu199, Arg206, and Asp282, we have produced a new
model of the peptide ligand binding site on C5aR, which accom-
modates structure/activity relationships that define antagonist
function for 2, 3, and analogues (21).
EXPERIMENTAL PROCEDURES
Construction of Human C5aR Mutants—The mutant C5aRs, I116A
and V286A, were constructed by overlap extension mutagenesis as
described previously (15). The C5aR mutant clones were sequenced
using ABI Big Dye terminator cycle sequencing kit, and the correct
constructs were purified using Nucleobond kit PC500 (Macherey-Na-
gel). The production of the C5aR receptor mutants R175A, R175D,
E199K, R206A, double mutant E199K/R206A, and D282A have been
previously described (14, 19, 22, 23).
Transfection and Cell Culture—RBL-2H3 cells were routinely cul-
tured in Dulbecco’s modified Eagle’s medium plus 10% (v/v) fetal calf
serum, which was supplemented with 400 mg/liter G418 for transfected
cells, at 37 °C, 5% CO2. RBL-2H3 cells were transfected by electropo-
ration, as previously described (23). A monoclonal antibody (S5/1; Se-
rotec) that recognizes the N-terminal sequence of the C5aR was used to
sort the highest 50% of transfected cells on a BD Biosciences Vantage
flow cytometer in two rounds of fluorescence-activated cell sorting.
Production of Peptides and Recombinant Ligands—The ligands used
in this study are shown in Table I. C5a, V3, C5a[Ala74], and C5a
des-Arg74 were produced in Escherichia coli and purified by the meth-
ods described in Crass et al. (23). Agonist and antagonist peptides,
synthesized as described previously (21), were supplied by Promics Pty
Ltd. (Queensland, Australia). All cyclic peptide antagonists were N-
acetylated at the N terminus except 3. An N-acetylated form of 3 had
identical properties to the non-acetylated form at the C5aR in RBL cells
(data not shown). Polypeptide C5a receptor antagonist C5aRA (24) was
a generous gift from Joerg Kohl (Medizinische Hochschule, Hannover,
Germany), and antagonist V2[Glu68] was made as described (25).
Measurement of Receptor Activation—Receptor activation in RBL
cells was measured as the release of -hexosaminidase from intracel-
lular granules as described (26). The percentage of -hexosaminidase
release was calculated as a percentage of the release stimulated by a
high dose of C5a (1 M). Total -hexosaminidase content was deter-
mined after cell lysis with 0.1% Nonidet P-40. Assay of the antagonist
activity was performed as described above except that the antagonists
were added at varying concentrations for 15 min before the addition of
C5a, C5a des-Arg74, or V3 at a final concentration of 50 or 250 nM. IC50,
EC50, and S.E. values were obtained by nonlinear regression analysis
using GraphPad Prism 3.0.
Chemotaxis Assay—Chemotaxis was measured using a 48-well mi-
gration chamber (Neuroprobe), with a 5-m pore polycarbonate mem-
brane. Cells were harvested by treatment with phosphate-buffered
saline plus 5 mm EDTA, resuspended in Dulbecco’s modified Eagle’s
medium plus 0.1% bovine serum albumin at 106/ml, and placed in the
top chamber. Dulbecco’s modified Eagle’s medium plus 0.1% bovine
serum albumin containing C5a, C5a des-Arg74, V3, or antagonist pep-
tides was placed in the lower chamber, and the apparatus was incu-
bated at 37 °C for 2 h. Cells were mechanically removed from the upper
surface of the membrane, which was then fixed in methanol for 30 s and
stained with a 0.1% solution of toluidine blue in 0.1 M sodium phos-
phate, pH 5.5, for 10 min. The numbers of migrated cells was measured
by densitometry using an imaging system (Alpha Innotech Corp.). In
some cases the relationship between the observed density of staining
and cell number was confirmed by counting stained cells in three fields
at a 40 magnification. Migration was calculated as a percentage of
migration of positive control (WT-C5aR cells to 1 nM C5a) included in
every experiment after subtraction of migration in the absence of li-
gand. All experiments were performed in triplicate, with a minimum of
three repeats.
[125I]C5a and ([3H]3CCO)(Phe)-cyclo-[Orn-Pro-D-Cha-Trp-Arg] Bind-
ing Assays—Binding assays using 50 pM [125I]C5a or 830 pM
([3H]3CCO)(Phe)-cyclo-[Orn-Pro-D-Cha-Trp-Arg] ([
3H]Ac-3) were per-
formed as previously described on either adherent C5aR-transfected
RBL cells (23) or isolated human polymorphonuclear granulocytes
(PMNs) (18). IC50 and Bmax values were obtained by nonlinear regres-
sion and Scatchard analyses, respectively, using GraphPad Prism 3.0.
Ligand Docking to a Homology Model of C5aR—Docking studies
were carried out on antagonist peptides 2 and Ac-3 using a homology
model of the C5aR,2 based on the crystal structure of bovine rhodopsin
(27). The homology model was constructed using the Homology module
within InsightII molecular modeling suite (Accelrys Inc., InsightII Mod-
eling Environment, Release 200.1, 2004, Accelrys Inc., San Diego, CA).
In this model of C5aR, Arg175 and Glu199 are located just above the top
of helices 4, and 5, respectively, but their predicted positions have a
high degree of uncertainty since the model is only based on sequence
homology with the transmembrane helices of rhodopsin. In contrast,
Arg206 is at the extracellular face of helix 5, and its location can be
predicted with more confidence.
Docking studies were carried out using the flexible ligand docking
program Gold Version 2.1. The most recent and best defined (21) NMR-
derived solution structures of 2 (21) and Ac-3 (17) were used as starting
points for ligand docking. We have created a series of structure models
for C5aR either with a Cys188–Cys109 disulfide bond that closes the
loops onto the transmembrane regions or without a disulfide bond and
loops directed away from the transmembrane region, which is then
exposed for extracellular access. Models were generated using the Ho-
mology module within InsightII 2000.1. The receptors were prepared
for docking by assigning charges and potentials and adjusting the side
chains of specific residues where necessary (Asp282, Arg206). The ligands
used were based on the NMR structures that we have previously pub-
lished and refined (21) for the cyclic and acyclic antagonists (17, 21).
Docking studies were carried out using Gold Versions 2.1, and results
were viewed using InsightII. All modeling and docking was performed
on an SGI R12000 octane work station.
RESULTS
Expression of Mutant Human C5aR in RBL-2H3 Cells—Wild
type (WT) and mutant (I116A, V286A) C5aR were transfected
2 P. K. Madala, J. D. A. Tyndall, and D. P. Fairlie, manuscript in
preparation.
TABLE I
Peptide sequences
Peptide 1 (N-Methyl-Phe)-Lys-Pro-D-Cha-Cha-D-Arg-CO2H
Peptide 1-L-Arg (N-Methyl-Phe)-Lys-Pro-D-Cha-Cha-Arg-CO2H
Peptide 1-amide (N-Methyl-Phe)-Lys-Pro-D-Cha-Cha-D-Arg-CONH2
Peptide 2 (N-Methyl-Phe)-Lys-Pro-D-Cha-Trp-D-Arg-CO2H
Peptide 3 Phe-cyclo-[Orn-Pro-D-Cha-Trp-Arg]
Peptide 3-XXXa Phe-cyclo-[Orn-Pro-D-Cha-XXX-Arg]
Peptide Ac-3 (N-Acetyl-Phe)-cyclo-[Orn-Pro-D-Cha-Trp-Arg]
Peptide [3H]Ac-3 (3H3CCO)(Phe)-cyclo-[Orn-Pro-D-Cha-Trp-Arg]
Peptide 4 Tyr-Ser-Phe-Lys-Pro-Met-Pro-Leu-D-Ala-Arg
Peptide 5 Tyr-Phe-Lys-Ala-Cha-Cha-Leu-D-Phe-Arg
V3 C5a des-Arg74 (C27R, E32A, E60R, D69A, Q71L)
V2[Glu68] C5a des-Arg74 (C27R, V56A, V57A, K68E, D69N, M70T)
C5aRA Jun-pIII/Fos-C5a des-Arg74(H67F, D69R, M70S, Q71L, G73R)
a XXX, Phe, His, Bta, 1-Nal, 2-Nal, or homophenylalanine (hPhe).
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into RBL-2H3 cells, and stable transfectants were obtained by
selection with G418. Homogenous populations of cells were
collected by two rounds of fluorescence-activated cell sorting,
selecting for the top 50% expressing cells using an anti-C5aR
monoclonal antibody. Receptor expression levels were meas-
ured by the specific binding of [125I]C5a (Bmax) to detect active
receptor and by immunofluorescence to detect total receptor
(Fig. 1). By these criteria WT and I116A-C5aR binding levels
were similar, but V286A-C5aR showed reduced binding of
[125I]C5a despite similar levels of receptor expression as shown
by immunofluorescence. Degranulation in response to a high
dose of C5a (1 M) was also assessed and was found to vary
widely between cell lines (Fig. 1). I116A-C5aR had a maximal
release of only 10% of total -hexosaminidase, similar to that
found previously for R206A-C5aR and E199K/R206A (14). The
expression and maximal secretion by cells transfected with
R175A and R175D-C5aR have been also been described previ-
ously (22). Both of these mutant receptors are activated only
weakly by C5a but can be stimulated effectively by a variant of
C5a des-Arg74 (V3) isolated by selection from a phage display
library (22). R175A secretes50% of total -hexosaminidase in
response to 1 M V3, whereas R175D secretes to a lower max-
imum level. E199K- and D282A-C5aR have been shown to be
expressed at high levels and to secrete substantial amounts of
-hexosaminidase in response to C5a (14, 23). The strength of
the degranulatory response is reduced by some mutations of
C5aR (results are presented here and elsewhere e.g. Ref. 22),
an effect that does not correlate with either C5aR expression or
C5a binding and may be due to partial misfolding of mutant
receptor. However, the functional response used to measure the
activity of ligands depends only on the contribution of properly
folded receptors, and there is clearly sufficient active receptor
to stimulate measurable degranulation in all cases (14).
The Effects of Mutation of C5aR Residues on Receptor Affin-
ity for C5aR Ligands—The affinities of WT and mutant C5aR
for the full agonist C5a and the partial agonist C5a des-Arg74
were measured by pretreating transfected RBL cells with these
agents, then incubating with 50 pM [125I]C5a (Table IIA). Only
the mutation of Arg175 caused a substantial loss of affinity for
C5a, with 30- and 152-fold decreases observed for R175A and
R175D, respectively. In contrast, mutation of either Ile116 or
Val286 increased affinity for C5a des-Arg74, whereas other mu-
tations had no effect or caused only a small decrease (R175D).
The binding of peptide ligands was increased in most cases
measured, with only R175D-C5aR showing substantially de-
creased affinities for the ligands relative to WT-C5aR. These
data suggest that mutation of these residues, with the excep-
tion of R175D, have relatively small effects on the overall
energy of interaction of these ligands for the receptor.
Peptide Ligand Binding Sites on C5aR—To determine
whether linear and cyclic peptide antagonists bind to the same
site on C5aR, competition binding studies using radiolabeled
cyclic antagonist [3H]Ac-3 were performed on human PMNs
(Table IIB). C5a competed for [3H]Ac-3 binding with a 6-fold
higher IC50 than for [
125I]C5a, confirming the high affinity of
cyclic antagonist for C5aR. The linear antagonist 2 also ap-
peared to have a higher affinity when competing for [3H]Ac-3
binding relative to [125I]C5a. Two forms of cyclic antagonist,
Ac-3 and 3, had comparable affinities when competing with
[125I]C5a or [3H]Ac-3 for C5aR binding (Table IIB). These data
support the idea that C5a and the peptide ligands (agonist 2
and antagonist 3) bind to the same (or a very similar) site on
C5aR.
The Effects of Mutation of C5aR Residues on C5aR Ago-
nists—The responses of mutated receptors to C5a largely cor-
related with binding affinity. In contrast, the response to the
partial agonist C5a, des-Arg74 was completely inhibited in sev-
eral cases (R206A-, R175A- or R175D-, E199K-C5aR), suggest-
ing a selective loss of responsiveness in the absence of the Arg74
side chain (Table IIC). The agonist form of the linear peptide, 1,
was a superagonist at several mutant receptors (I116A-,
V286A-, D282A-, R175A- or R175D-C5aR) stimulating a
greater degree of activation than 1 M C5a/V3, but it failed to
activate R206A-C5aR. Two other peptide agonists of C5aR, 4
and 5, also stimulated supramaximal levels of release from the
receptor mutants I116A-, V286A-, D282A-C5aR. R175A- or
R175D-C5aR did not respond to these peptides, whereas
R206A, not activated by 1, showed a substantial response to 4
and 5. In contrast, E199K-C5aR responded well to peptide 1
but very poorly to 4 and 5. The presence of an L-Arg at the C
FIG. 1. C5a receptor expression by transfected RBL cells. Receptor expression levels on untransfected RBL cells (NX) or RBL cells
transfected with WT-, I116A-, or V286A-C5aR were measured by immunofluorescence (open bars) and are shown as log median channel numbers;
means are from a single experiment performed in duplicate. Expression levels were also assessed by Scatchard analysis of [125I]C5a binding
(hatched bars), shown as Bmax values in dpm/well to adherent cells in a 96-well microtiter plate from n separate experiments (see Table I)
performed in triplicate. The maximal degranulation levels of these cell lines (filled bars) in response to 1 mM C5a are shown as the percentage of
total cellular -hexosaminidase mean  S.E. released into the supernatant from at least three separate experiments performed in triplicate.
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terminus of peptides 4 and 5may have been responsible for this
mixed pattern of receptor activation. However, a variant of
peptide 1with L-Arg instead of D-Arg (1-L-Arg) failed to activate
either R206A or E199K-C5aR, suggesting that additional fac-
tors must be involved. The C-terminal amide analog of 1 (1-
amide) is a substantially weaker agonist at WT-C5aR than 1,
suggesting that a C-terminal carboxylate might be important
for agonist activity. Interestingly, receptors R206A- and
R175A- or R175D-C5aR showed a reverse response, indicating
that 1-amide was a stronger agonist at these receptors than 1.
The linear antagonist, 2, did not stimulate secretion from
cells transfected with WT or mutant C5aR at concentrations up
to 100 M, with the exception of I116A-C5aR. In these cells, the
response to 2 had an EC50 of 622 nM, similar to the agonist
peptide 1 (Table IIC). Antagonist 2was, however, only a partial
agonist, stimulating a maximal release of 62% of the response
to 1 M C5a. In contrast, the cyclic antagonist 3 (and Ac-3) had
no stimulatory effect at concentrations up to 100 M (Table IIC)
but did act as a partial agonist at R175D-C5aR, stimulating
cells to the same level as C5a, with an EC50 of 2410 nM (Table
III). Neither of two polypeptide C5aR antagonists, derived by
mutagenesis of C5a, namely C5aRA and V2[E68], had any
TABLE II
Affinities of C5a and C-terminal analogues for C5a receptor and selected receptor mutants
A. C5a receptor mutants expressed in RBL cells
WT-C5aR I116A-C5aR V286A-C5aR
pD2I  S.E.
a IC50
b pD2I  S.E. IC50 pD2I  SE IC50
C5a 7.86  0.03 14.0 8.67  0.06*** 2.12 7.54  0.12*** 28.5
C5a des-Arg74 6.21  0.08 604 7.24  0.15*** 57.0 7.12  0.10*** 75.0
2 5.75  0.14 1,770 5.86  0.15NS 1,360 6.37  0.26* 419
3 6.87  0.06 134 7.18  0.08** 65.3 7.32  0.19* 47
1 4.81  0.13 15,500 5.93  0.15*** 1,180 5.62  0.20** 2,380
1-amide 4.58  0.17 26,400 5.04  0.11* 9,200 5.36  0.11*** 1,440
R206A-C5aR R175A-C5aR R175D-C5aR
pD2I  SE IC50 pD2I  SE IC50 pD2I  SE IC50
C5a 7.31  0.08*** 48.9 6.38  0.13*** 420 5.67  0.17*** 2130
C5a des-Arg74 6.36  0.12NS 440 6.13  0.25NS 734 5.64  0.22** 2294
2 5.22  0.47NS 6036 ND 4.00
3 ND ND ND
1 5.71  0.20** 1945 ND 4.00
1-amide 5.10  0.17* 7953 ND 4.00
B. C5a receptor in human polymorphonuclear neutrophils
[I125]C5a [3H]Ac-3
pD2I  SE
a IC50
b pD2I  SE IC50
C5a 9.14  0.07 0.745 8.45  0.10 3.59
2 5.46  0.07 4280 6.71  0.04 195
3 6.76  0.15 174 7.72  0.17 19.2
Ac-3 6.75  0.11 283 7.07  0.02 16.9
C. Comparative agonist potencies on mutant C5a receptors in transfected RBL cells
WT-C5aR I116A-C5aR V286A-C5aR R206A-C5aR
pD2E  SE
c EC50
d pD2E  SE EC50 pD2E  SE EC50 pD2E  SE EC50
C5a 8.24  0.03 5.82 (100)e 8.21  0.0388 6.24 (100) 7.77  0.02*** 17.0 (100) 7.40  0.04*** 39.4 (100)e
C5a des-Arg74 7.67  0.07 21.2 (79)e 7.07  0.13*** 84.4 (50) 7.52  0.07** 30.1 (58) 5.00e
C5a[Ala74] 6.57  0.12 272 (79)e ND ND 5.00e
3 4.00 4.00 4.00 4.00
2 4.00 6.21  0.12 622 (62) 4.00 4.00
1 6.64  0.14 228 (96)e 7.01  0.06* 98.5 (125) 6.33  0.11* 469 (119) 4.00e
1-L-Arg 5.51  0.24 3,106 (14) 6.44  0.87NS 366 (9) ND 4.00
1-amide 6.01  0.11 973 (83) 6.18  0.11NS 662 (104) 5.45  0.14** 3,580 (119) 5.61  0.21* 2,440 (22)
4 5.85  0.10 1,430 (96) 6.05  0.10* 898 (133) 5.00  0.12*** 10,100 (122) 4.01  0.11*** 96,750 (92)
5 6.49  0.09 322 (100) 6.42  0.13NS 384 (120) 6.20  0.08** 629 (107) 5.53  0.19*** 2,970 (68)
D282A-C5aR R175A-C5aR R175D-C5aR E199K-C5aR
pD2E  SE EC50 pD2E  SE EC50 pD2E  SE EC50 pD2E  SE EC50
C5a 7.77  0.04*** 16.9 (100)e 6.30  0.17*** 503 (55)f 6.65  0.33*** 223 (21)f 8.21  0.08NS 6.12 (100)f
C5a des-Arg74 7.62  0.07NS 24.4 (91)e 5.00f 7.52  0.07** 30.1 (58)f 5.00g
C5a[Ala74] 7.50  0.07*** 29.0 (88)e 5.00 ND 5.00
3 4.00 4.00 5.62  0.48 2,410 (23) 4.00
2 4.00 4.00 4.00 4.00
1 6.34  0.12* 442 (112)e 6.21  0.10* 620 (142)f 4.91  0.10*** 12,430 (187)f 6.79  0.10NS 163 (101)f
1-L-Arg ND 5.47  0.15NS 3,383 (108) 4.00 4.00
1-amide 5.54  0.15* 2,910 (100) 6.43  0.05** 372 (152) 5.45  0.14** 8,469 (101) 5.95  0.09NS 1,120 (91)
4 4.12  0.10*** 70,640 (129) 4.00 4.00 4.06  0.09*** 87,100 (120)
5 4.06  0.06*** 87,960 (113) 4.00 4.00 4.26  0.18*** 55,200 (60)
a pD2I  logIC50.
b IC50  concentration (nM) resulting in 50% inhibition of the maximum binding. Difference from WT-C5aR: NS, not significant. *, 5%; **,
0.5%; ***, 0.005% (two-tailed t test). All experiments are n  2 or greater.
c pD2E  log EC50;
d EC50, concentration (mM) resulting in 50% of maximal degranulation;
e,f data originally published in Cain et al. (Ref. 14 (e) or Ref. 22 (f)), respectively, and shown here for comparison purposes. Significantly different
from WT-C5aR: *, 5%; **,  0.5%; ***, 0.005% (two-tailed t test). All experiments are n  2 or greater.
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agonist activity on any mutant C5aR at concentrations of up to
3 and 10 M, respectively (data not shown).
These data were confirmed by studies using chemotaxis as
an even more sensitive read-out of receptor activation (Fig. 2).
WT-C5aR cells migrated very efficiently to C5a (maximum
migration at 1 nM) but were less sensitive to C5a des-Arg74
(maximum at 100 nM). In contrast, D282A-C5aR cells migrated
equally well to both stimuli (maxima at 100 nM). E199K- and
R206A-C5aR cells responded more strongly to C5a (maxima at
10 nM and 1 M, respectively) than to C5a des-Arg74 (maxima
10 M in both cases). R175A (and R175D, data not shown)
displayed only very weak responses to C5a, but V3 stimulated
higher levels of migration (maxima at 1 nM). As expected from
the degranulation data, I116A-C5aR responded quite poorly to
C5a, with 50% of the migratory response of WT-C5aR cells,
although the maximum response occurred at 1 nM C5a. The
linear antagonist peptide 2 stimulated migration in I116A but
not WT-C5aR cells, whereas the cyclic antagonist peptide 3 had
no effect on either type of receptor.
The Effects of Mutation of C5aR Residues on Antagonist
Activity—The antagonist activities were initially measured by
preincubating cells with antagonist, then adding C5a (or V3 for
R175D-C5aR) to a final concentration of 250 nM (Fig. 3, Table
III). Under these conditions, 3 acted as a complete antagonist
in all cases except R175D, where only 88% of the degranulation
response to V3 was inhibited, with similar IC50 values for WT
and all mutant receptors (Fig. 3, Table III). In contrast, 2 was
a full antagonist at V286A-, E199K-, R206A-, and E199K/
R206A-C5aR and a partial antagonist for both WT and I116A-
C5aR (64% inhibition at 100 M antagonist) but had no signif-
icant effect on R175D-C5aR (50% inhibition at 100 M). In
separate experiments at a lower dose of C5a (50 nM), 100 M 2
completely inhibited activation of WT-C5aR but inhibited only
40% of the response of I116A-C5aR, whereas 3 remained a full
antagonist at both receptors (data not shown).
The Effects of Substitution at Residue 5 in Cyclic Antagonist
3—To determine the effects of the size and hydrophobicity of
the side chain on the agonist activity of this peptide at WT-
C5aR and I116A-C5aR, the critical antagonism determining
Trp residue at position 5 of 3 was substituted by a series of
amino acids possessing hydrophobic side chain rings. The re-
ceptor affinities and antagonist potencies of this series of pep-
tides have been tested on human PMNs (21). Three peptides, 3-
benzothiazolealanine (3-Bta), 3-Phe, and 3-1-naphthylalanine
(3-1-Nal) bound C5aR with a similar affinity to 3 and were
effective antagonists, although 3-Bta had a significantly higher
IC50 value than 3. When tested on transfected RBL cells, no
agonist activity was detected with any of the peptides at con-
centrations below 100 M (data not shown), but at 100 M one
peptide, 3-Bta, caused a significantly higher secretory response
from I116A-C5aR relative to the response to 3 (Fig. 4). 3-1-Nal
did not stimulate significant levels of secretion from I116A-
C5aR relative to 3, but when compared with the effects on
WT-C5aR, 3-1-Nal had a significantly greater effect on I116A-
C5aR (t test, p  5%). Neither WT nor V286A-C5aR showed
any significant secretory response to any of these peptides.
Receptor-Ligand Modeling—A previous model for C5aR
binding to peptide 2 used a presumed interaction between Arg6
carboxylate of 2 with Arg206 of C5aR to orient the ligand with
the receptor (1). Dockings were carried out on a model that
allowed for little or no movement of the receptor residues so a
different rotamer of a particular residue would produce differ-
ent docking results. We have now repeated this work (Fig. 5A)
using a homology model of the C5aR created without the
Cys188–Cys109 disulfide bond so that the loops are open and not
available for interaction during the ligand docking. We checked
the model of Bourne and co-workers (1) using GOLD and au-
tomated dockings of 2 (the positions of the carbonyl oxygens
from the NMR turn structure were used to restrain ligand
docking). Using this alternative approach to the earlier model,
we found that the D-Arg6 side chain did not project deep within
the helices (not shown) but, instead, consistently lay close to
residues in the extracellular loop between helix 4 and helix 5,
particularly Glu199. We think that D-Arg6–Glu199 ligand/recep-
tor salt bridge formation is more likely than insertion of the
D-Arg6 side chain into a hydrophobic pocket formed by aromatic
residues. If such an interaction between D-Arg6 and Asp282
occurs, as suggested here and elsewhere (14), it would preclude
the other interactions with D-Arg6 or suggest a dynamic bind-
ing mechanism in which initial transient interactions (e.g. be-
tween D-Arg6 and Glu199) are followed by more durable inter-
actions (e.g. between D-Arg6 and Asp282).
Fig. 5B shows a homology model of the C5aR, created with a
Cys188–Cys109 disulfide bond and extracellular loops closed
into which compound Ac-3 was fitted using automated docking.
Two receptor-ligand constraints were used; C Ile116 was re-
strained to within 5 Å from the center of the indole ring of Trp5
(C2), and Asp282 (modeled into the extracellular loop 3 that
immediately precedes helix 7) was constrained to form an H-
bond with the side chain of Arg6. A consistent result was
obtained from 10 iterations. The Ac-Phe side chain inserted
itself between helices 6 and 7 of the receptor in the vicinity of
Ile263 (helix 6) and Leu207 and Phe211 (helix 7). Arg206 in this
case is modeled as having an interaction with the proximal
Glu199. The D-Cha residue at position 4 points toward the
outlying helix 4 but closer to helix 3 and is close to Pro113,
Ser114, Arg197 and the salt bridge between Arg206 and Glu199.
Trp5 is adjacent to Val286, Ile116, and Pro113. Because of the
constraint imposed on Asp282, Arg6 is close to this as well as
Gln259 and Tyr258, with Asp181 also presenting a possible in-
teraction given that this is a closed loop model. Based on this
model the Arg206–Glu199 interaction appears to be likely.
However, a feature of this closed loop model is that receptor
residues in the loops may form important salt bridges/contacts
TABLE III
Comparative antagonist potencies on mutant C5a receptors in transfected RBL cells
WT-C5aR I116A-C5aR V286A-C5aR R206A-C5aR
pD2I  SE
a IC50
b pD2I  SE IC50 pD2I  SE IC50 pD2E  SE EC50
3 7.32  0.12 54.1 (100) 7.55  0.07* 28.3 (94) 7.50  0.03NS 31.4 (100) 8.51  0.11*** 3.09 (100)
2 5.13  0.16 7386 (64) 6.53  0.21*** 265 (64) 5.57  0.10* 2667 (100) 7.50  0.07*** 31.4 (100)
O282A-C5aR E199K/R206A-C5aR R175D-C5aR E199R-C5aR
pD2I  SE IC50 pD2I  SE IC50 pD2I  SE IC50 pD2E  SE EC50
3 6.40  0.09*** 392 (92) 7.62  0.13NS 24.2 (100) 5.15  0.19*** 7097 (88) 6.88  0.04*** 133 (96)
2 5.32  0.12NS 4830 (74) 7.01  0.14*** 97.3 (100) 4.00 5.35  0.07NS 4433 (96)
a pD2I, logIC50.
b IC50, concentration (nM) resulting in 50% inhibition of the maximum degranulation. Significantly different from WT-C5aR: *, 5%; **, 0.5%;
***, 0.005% (two-tailed t test). All experiments are n  2 or greater.
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with one another, although it is not possible based on homology
modeling alone to pinpoint which of these might be occurring
(e.g. Arg206–Asp191/Glu180, Arg175–Asp191/Glu180, Asp282–
Lys185/Arg178). If any of those interactions occur, then the li-
gand Arg6 residue could speculatively be oriented in two con-
ceivable ways. If Arg6 of Ac-3 is oriented toward Asp282, it may
interrupt a potential linkage between Asp282 and Arg178, which
are both in the loop region above the ligand binding pocket.
Alternatively, if Arg6 is oriented toward Arg206, it may disrupt
the possible salt bridge between Arg206 and Asp191 or Glu180.
Another docking experiment was conducted with the same
constraints as those presented in Fig. 5B using a homology
model lacking the disulfide bridge and, thus, without the closed
loops. Compound Ac-3 was docked into the receptor using au-
tomated docking, with two receptor-ligand constraints (C
Ile116 was restrained to 5 Å from the center of the indole ring
of Trp5 (C2); Asp282 was constrained to form a H-bond with the
side chain of Arg6 (modeled into the extracellular loop 3 that
immediately precedes helix 7)). A very consistent result was
obtained for five docking iterations. The Arg6 side chain was
within 5 Å of Val286, Cys285, Asp282 (constrained), Thr261,
Gln259, Gly262, and Tyr258. The Trp5 side chain lies within 6 Å
of Leu117, Ile116, Pro113, Val286, Ala289, Cys285, and Tyr258. The
remaining interactions were within 6 Å of the D-Cha side chain
(Arg197, Glu199 (constrained), Arg206, and Pro113). The Ac-Phe
side chain is in the same position discussed above, between
FIG. 2. The stimulation of migration of transfected RBL cells. RBL cells transfected with WT or mutant C5aR were stimulated to migrate
through 5-m pore size polycarbonate filters in response to C5a (●), C5a des-Arg74 (E), V3 (f), peptide 2 (ƒ), or peptide 3 (‚). Migration was
measured by staining filters with toluidine blue and expressed as a percentage of the migration of WT-C5aR cells to 1 nM C5a. The results are the
means  S.E. of at least three separate experiments performed in triplicate.
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helices 6 and 7 of the receptor, in the vicinity of Ile263 (helix 6)
and Leu207 and Phe211 (helix 7).
Fig. 5C involves the alternative homology model of C5aR
created without a Cys188–Cys109 disulfide bond, leaving the
loops open. In these separate experiments Ac-3was docked into
this open model of C5aR, the Arg6 side chain and Glu199 side
chain being tethered with a salt bridge (hydrogen bond con-
straints) and the Trp5 side chain tethered to Ile116 as above.
Receptor residues within 5 Å of Arg6 were Arg197, Glu199 (con-
strained), Arg201, Val177, Leu173, Pro170, Ser110. Trp5 was
within 6 Å of receptor residues Pro113, Ile116, Leu117, Val286,
and Tyr258. D-Cha4 was within 6 Å of Val286, Tyr258, Asp282,
Cys285, Thr261, and Gly262. Essentially the latter interactions
are the reverse of that seen in the first two models (i.e. Arg6
interacts where D-Cha was positioned).
DISCUSSION
Ile116/Val286—The side chains of C5aR residues Ile116 and
Val286 in the 3rd and 7th transmembrane helices, respectively,
have been proposed to form part of an activation switch for
C5aR (1). We have examined this proposal in detail using
linear and cyclic peptide antagonists as probes to determine
whether this is a general target for C5aR antagonists. The data
presented in this paper contrast strikingly with the effects of
I116A and V286A mutations in the human C5aR expressed in
yeast, where both of these mutations caused complete loss of
C5a receptor activity (1). The mutation of such “putative acti-
vation switch residues” had the general effect herein of increas-
ing receptor affinity for C5aR ligands. In contrast, the EC50 for
I116A-C5aR activation by C5a was increased 3-fold relative to
WT-C5aR. Therefore, although I116A-C5aR has a higher affin-
ity for agonists, the mutation decreases the efficiency of recep-
tor activation by C5a, C5a des-Arg74, and agonist peptide 1.
Mutation at Ile116 or Val286 caused no change in affinity for
either the linear antagonist 2 or cyclic antagonist 3, although
both C5aR mutants had a higher affinity for the cyclic antag-
onist over the linear form. 3 was a full and potent antagonist of
RBL cell degranulation through both receptors, with no signif-
icant difference in IC50 values. In contrast, the pattern of
antagonism by 2 was more complex. This peptide was a full
antagonist for V286A-C5aR and R206A-C5aR but inhibited
WT-C5aR and I116A-C5aR by only 60% in response to 250 nM
C5a. 2 is actually a partial agonist at I116A-C5aR, and there-
fore secretion is a balance between the antagonistic effects of
peptide on secretion induced by C5a and the agonistic effects of
FIG. 3. Inhibition of C5a-stimulated degranulation by hexapeptide antagonists in RBL cells transfected with wild type and
mutant C5aR. RBL cells transfected with WT or mutant C5aR were incubated with the C5aR antagonists peptide 3 or 2 for 15 min before the
addition of 250 nM C5a. Degranulation was assessed as the release of -hexosaminidase, as described under “Experimental Procedures.” Results
are the means of at least three separate experiments performed in triplicate S.E.
FIG. 4. The stimulation of degranu-
lation in transfected RBL cells by cy-
clic hexapeptides containing substi-
tutions at position 5. RBL cells
transfected with wild type (open bars)-,
I116A (filled bars)-, or V286A-C5aR
(hatched bars) were incubated with the
100 M peptide 3-XXX5, where XXX 
Trp, homophenylalanine (hPhe), Bta,
Phe, His, 2-Nal, or 1-Nal. Degranulation
was assessed as the release of -hex-
osaminidase, as described under “Experi-
mental Procedures” and is shown as a
percentage of maximal degranulation in
response to 1 M C5a. Results are the
means of three separate experiments per-
formed in triplicate  S.E. Significantly
different to the response to 3. **, p  0.
5%.
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peptide alone. On WT-C5aR, 2 is not an agonist but failed to
completely inhibit C5a activity, presumably due to competition
with C5a for the ligand binding site. The cyclic peptide 3
remains a potent antagonist with no detectable agonist activity
on either I116A- or V286A-C5aR despite also having Trp at
position 5. The antagonist activity is unlikely to be related to
the lack of a free carboxylate at the C terminus, since 1-amide
is a potent agonist at WT-, I116A-, and V286A-C5aR, suggest-
ing that simple deletion of the interaction with the C-terminal
carboxylate is insufficient to generate an antagonist.
Substitution of Trp5 by different amino acids generally re-
duces receptor affinity and antagonist activity (21) but only the
sulfur-containing heterocyclic amino acid Bta produces a cyclic
peptide with significant agonist activity at I116A-C5aR rela-
tive to 3. This weak gain of agonist activity correlates with the
loss of antagonist potential, as 3-Bta5 is a less potent antago-
nist than 3 at WT-C5aR on PMNs. However, the gain in agonist
potential at I116A of 3-Bta5 is unexpected because Trp and Bta
differ only at the heteroatom. Increased agonist activity is
unlikely to be due simply to improved binding of this bulkier
side chain to C5aR, because 3-Bta5 binds PMN C5aR with an
identical affinity to 3. In contrast 3-Phe5, with a less bulky
aromatic side chain, binds to PMNs with a similar affinity to 3
but remains a potent antagonist. Interestingly, a linear peptide
containing Phe at position 5 is an agonist even at WT-C5aR (5),
which supports the suggestion that the cyclic peptide contains
additional determinants of antagonist activity.
Although the precise mechanism of C5aR antagonism by
peptides is still unclear, the differential responses to receptor
mutations by cyclic versus linear hexapeptides and also the two
polypeptide antagonists, C5aRA and V2[Glu68], reported here
suggest that antagonist action is not critically related to inter-
ference by Trp5 at a putative activation trigger formed by Ile116
and Val286 (1). However, Ile116 does have a role in receptor
activation because the activation efficiency of I116A-C5aR is
lower than WT-C5aR. Receptor activation may require the
residue at position 5 of the hexapeptide ligand to interact with
residues buried deeper in the hydrophobic transmembrane do-
main of C5aR than Ile116. The size of the Trp5 side chain in
antagonist 2may prevent this occurring due to steric hindrance
by Ile116, whereas the substitution of Ile116 by the smaller
residue Ala allows deeper penetration of the receptor core by
Trp5 and, therefore, receptor activation by peptide 2. Thus,
linear antagonist becomes the agonist simply because suffi-
cient space has been created for the more bulky Trp side chain
at position 5. However, any hypothesis of C5aR antagonism
must accommodate the observation that the cyclic peptide de-
rivative of 2, namely 3, remains an antagonist at I116A. It is,
thus, interesting that Trp5 is not essential for antagonism in
analogues of 3, as a W5F substitution results in comparable
antagonist potency for this ligand (21).
NMR studies have shown that the linear and cyclic peptides
have similar turn structures (17, 29) and compete similarly
with [125I]C5a or [3H]Ac-3 for the receptor, supporting the idea
that they bind at the same or a similar site on the receptor. The
significant difference between the peptides is, therefore, likely
to be rigidity, cyclization having locked 3 into the turn struc-
ture, whereas the linear peptide is capable of significant defor-
mation during binding. This ability to deform may allow side
chains at position 5 of the linear peptide to interact correctly
with the activation site after binding, whereas the rigidity of 3,
although permitting high affinity interactions with other re-
ceptor binding sites, may prevent position 5 side chains from
penetrating into the Ile116 pocket even when Ile116 is mutated.
The cyclic constraint certainly reduces the flexibility of the
antagonist, and this may also limit the capacity of the antag-
onist to alter shape in response to receptor mutations. This
hypothesis would explain the lack of agonist activity of 3-Phe5
on WT-C5aR and 3 on I116A-C5aR. The substitution of Trp5 by
the larger side chain of Bta (and to a lesser extent 1-Nal) may
allow the interaction of residue 5 with the receptor activation
site protected by Ile116, producing agonist activity at the I116A
mutant.
Arg206/Arg175—It has been proposed that the receptor inter-
action site for the C-terminal carboxylate of C5aR agonists is at
Arg206, a residue at the extracellular face of helix 5 (1). Muta-
tion of Arg206 to Ala has only a small effect on receptor activa-
tion by C5a (14) and does not abrogate antagonism by either
linear or cyclic antagonist (results herein). This mutation does,
however, appear to affect interactions with the agonist pep-
FIG. 5. Modeling the interaction between peptide antagonists
and the C5a receptor. A, cyclic antagonist (N-methyl-Phe)-Lys-Pro-
D-Cha-Trp-Arg-CO2H (2) docked into the C5a receptor model. The NMR
structure of the free ligand was used as a template to constrain the
conformation (based on H-bond acceptors) of the docked ligand. A con-
straint between Arg206 and the C-terminal carboxylate of Arg6 was used
to reproduce a previous model (1) in addition to the Trp5–Ile116 con-
straint. B, cyclic antagonist Ac-Phe-cyclo-[Orn-Pro-D-Cha-Trp-Arg]
(Ac-3) docked into the C5a receptor model. Two constraints were used;
one fixes a hydrogen bond between the Arg6 of the ligand and Asp282
(helix 7) of the receptor, and the second constrains the Trp5 side chain
(C2) of the ligand to within 5 Å of the C of Ile116 on helix 3 of the
receptor. C, cyclic antagonist Ac-3 docked into the C5a receptor model.
Two constraints were used; one fixes a hydrogen bond between the Arg6
of the ligand and Glu199 (Helix 5) of the receptor, and the second
constrains the Trp5 side chain (C2) of the ligand to within 5 Å of the C
of Ile116 on helix 3 of the receptor.
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tides, and only the amidated form of 1 has weak (but detecta-
ble) activity. Taken together with the observation that C5a
des-Arg74 binds to, but does not activate R206A-C5aR (this
paper and Ref. 14), it is possible that mutation of this receptor
residue perturbs the global structure of the receptor rather
than disrupting specific ligand interactions. This view is fur-
ther supported by the finding that a ligand-independent con-
stitutively active C5aR mutant (I124N/L127Q) can be com-
pletely deactivated by substitution of Arg206 by His (1).
Another potential receptor site for interaction with the C-
terminal carboxylate is Arg175, located either on the extracel-
lular face of helix 4 or in the adjacent loop. The analogous
residue (Arg161) in the closely related C3a receptor has been
proposed to interact with the C-terminal carboxylate of C3a
(28). We have previously shown that although C5aRs mutated
at Arg175 are only weakly activated by C5a, they can be
strongly activated by a mutant form of C5a des-Arg74 (V3),
isolated from a randomly mutated C5a des-Arg74 library (22),
suggesting that a specific and important interaction between
C5aR and C5a is lost when Arg175 is mutated to either Ala or
Asp. In this paper we have shown that 1-amide is equipotent
with 1 as an activator of Arg175 mutants, suggesting that
Arg175 may make an interaction with the C-terminal carboxy-
late of 1. It is also interesting to note that 3, with no free
carboxylate, is a weak activator of R175D. This suggests first
that the conversion of an antagonist to an agonist is not a
unique property of Ile116 and, second, that the C-terminal car-
boxylate of the ligand interacts in some way with Arg175. Fur-
thermore 1-L-Arg, with the C-terminal carboxylate oriented
differently to 1, can activate R175A to a greater extent than
C5a. Previously, Arg206 has been suggested to act as a “gate-
keeper” that must be displaced by the charged groups on the
ligand C-terminal Arg residue to allow the ligand carboxylate
to interact elsewhere on the receptor (13). A possible explana-
tion of our data is that the peptide carboxylate makes interac-
tions with both Arg206 and Arg175 at different points in the
receptor binding and activation process. Whereas our homology
modeling studies are more strongly supportive of a role for
Arg175 in stabilization of the inactive receptor state, perhaps by
weak polar interaction with residues such as Glu199, we note
that only a small (ligand-induced?) decrease in distance be-
tween helix 4 and helix 5 in our model could conceivably enable
interactions with both Arg175 and Arg206. These proposed
mechanisms cannot be distinguished from available data at
present.
Asp282/Glu199—We have previously shown that Asp282 at
the extracellular face of helix 7 interacts with the side chain of
Arg74 of C5a and with the C-terminal Arg in peptide analogs
(14, 22). The mutation of D282A decreases the affinity for cyclic
antagonist 3 10-fold but has no effect on affinity for the linear
antagonist. The mutation E199K has a similarly small effect on
antagonism, in contrast to the complete lack of responsiveness
of this mutant to agonists lacking a C-terminal Arg, such as
C5a des-Arg74 and C5a[Ala74], suggesting that in addition to a
previously demonstrated interaction between Lys68 and Glu199
(19, 23), the side chain of the C-terminal Arg74 residue inter-
acts with Glu199. However, the loss of this interaction after
mutation of Glu199 has no effect on the responsiveness to C5a,
possibly suggesting only a transient interaction between Arg74
and Glu199, with a more important interaction occurring be-
tween Arg74 (Arg6 of peptide ligands) and Asp282. This is clearly
shown by the mutation D282R, which has a very low respon-
siveness to C5a but a relatively normal response to C5a des-
Arg74 and similar ligands (14, 22).
A New Model for the Interaction of Peptide Ligands with
C5aR—Previously, it was proposed by Bourne and co-workers
(1) that Ile116 and Val286 of C5aR are key residues in determin-
ing whether C5a and its C-terminal analogs are agonists or
antagonists. That work involved a model based on manual
docking of an early NMR structure of the linear antagonist 2
into the receptor followed by energy minimization (SYBYL®).
They initially docked the ligand (NMR-derived structure show-
ing a turn) incorporating the Trp5–Ile116 interaction as well as
a presumed ligand/receptor interaction between the carboxy-
late at the C terminus of D-Arg6 with Arg206. This orientation
by default projects the D-Arg side chain deep within the space
between helices 3, 5, and 6, adjacent to aromatic residues
Tyr121/Phe211/Phe251. Based on the premise that position 5
(Trp) of the small molecule antagonist 2 becomes lodged in a
pocket defined by Ile116, Val286, and Ala289, it was conjectured
that mutation of the latter residues might alter antagonist/
agonist activity. Indeed the mutation I116A, which increases
the receptor space available for ligand occupation, does convert
2 from antagonist to agonist. A change in the ligand at position
5 from L-Trp to L-Cha also converted antagonist 2 to the agonist
1. Together, the results were consistent with one site on the
receptor being crucial for differentiating between agonist ac-
tivity and antagonism.
In the present paper we sought to test whether Ile116 and
Val286 participate in a general switching mechanism for receptor
activation or whether the previous observations (1) were ligand-
specific by examining the effects of receptor mutations for both 2
and a different antagonist, Ac-3. Because our data suggests that
antagonism by compound Ac-3 is not affected by mutation of
Ile116, it is likely that the antagonist mechanism proposed pre-
viously may indeed be specific for compound 2 (1). However, our
data do suggest that compounds with bulkier residues at position
5 are affected by mutation of Ile116, and so a receptor-ligand
interaction in the vicinity of Ile116 is a likely event.
Data presented in this paper do not support the earlier model
of the interaction between receptor and ligand proposed in (1),
and recent work strongly suggests an alternative interaction
between Asp282, a residue at the extracellular face of helix 7 of
C5aR, and the side chain of Arg6 (14). This has a profound
effect on the orientation of peptide ligand with respect to re-
ceptor. There is also evidence of an interaction between the
C-terminal carboxylate and Arg175, which means that the C-
terminal carboxylate cannot be located in the vicinity of Arg206
with any degree of certainty. The position of Arg175 is uncertain
in the transmembrane homology model of C5aR reported
herein because it is not in a transmembrane helix but rather in
the extracellular loop at the top of helix 4. However, by posi-
tioning the ligand Arg6 side chain close to Asp282 and ligand
Trp5 side chain in the vicinity of Ile116/Val286, new models of
C5aR complexed with antagonist peptides 2 and 3 have been
derived (Fig. 4). The interaction between Asp282 and Arg6 pre-
cludes the guanidinium group of Arg6 from binding deep within
the helical bundle. Given the length and flexibility of the argi-
nine side chain, there are more feasible interactions than the
proposed -cation interaction (1) deep within a hydrophobic
channel. Furthermore, movement of only selected receptor side
chains is highly subjective given the dynamic nature of this
system.
The roles of Arg175 and Arg206 might be to stabilize helices 4
and 5. Whereas peptide Ac-3 does not contain a free carboxy-
late group, peptide 2 does and if positioned in the vicinity of
Arg206 as proposed, it may interrupt salt bridges that help
stabilize the transmembrane helices. This may be a key mech-
anistic feature of agonist action. The mutation E199K affects
the response to all ligands except C5a, so it is possible that this
is because Glu199 interacts with Arg206 (as shown in Fig. 4A) to
help stabilize helix 5 of the receptor. Perhaps C5a can itself
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help stabilize this helix and, thus, is insensitive to this muta-
tion. It is notable that C5aR doubly mutated at Glu199 and
Arg206 responds to agonists such as C5a and C5a des-Arg74 (14)
and antagonists 2 and 3 in a similar fashion to R206A (data
presented here).
Conclusions and Comments—Based on the balance of evi-
dence for effects of mutations in the C5a receptor on the affinity
and agonist/antagonist potencies of C5a and small peptide li-
gands, together with our receptor-ligand modeling studies, we
suggest that terminal Arg residues of such ligands do not insert
into the hydrophobic pocket in the interior of the helix bundle
as previously proposed (1). The receptor and ligand mutagen-
esis and modeling studies in this paper present some new
testable hypotheses about the importance of charged residues
in the receptor, particularly Arg206, Glu199, Arg175, and Asp282,
and shed further light on the fitting of Arg side chains of small
peptide ligands into the C5a receptor.
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